Identification and validation of immune and diagnostic biomarkers for interstitial cystitis/painful bladder syndrome by integrating bioinformatics and machine-learning

Tao Zhou, Can Zhu, Wei Zhang, Qiongfang Wu, Mingqiang Deng, Zhiwei Jiang, Longfei Peng, Hao Geng, Zhouting Tuo, Ci ZouFrontiers in Immunology 2025 · DOI

TL;DR

This study leverages bioinformatics and machine learning to identify novel diagnostic biomarkers for Interstitial Cystitis/Painful Bladder Syndrome (IC/BPS), a condition with elusive etiology and challenging diagnosis. The research pinpoints PLAC8 as a promising biomarker that also plays a role in modulating the immune response and urothelial cell function, offering new avenues for diagnosis and potential therapeutic strategies.

What Problem Does This Paper Address?

Interstitial Cystitis/Painful Bladder Syndrome (IC/BPS) is a chronic condition characterized by bladder pain and urinary symptoms, significantly impacting patients' quality of life. Despite growing evidence suggesting a complex interplay of genetic predisposition, hormonal factors, autoimmune conditions, and chronic inflammation, the exact etiology of IC/BPS remains elusive. This lack of understanding poses a significant challenge for accurate diagnosis and effective treatment. Current diagnostic methods are often indirect, relying on symptom assessment and ruling out other conditions, leading to delays and misdiagnoses. The paper aims to address this by identifying reliable diagnostic biomarkers that can improve diagnostic accuracy and shed light on the underlying immune mechanisms of IC/BPS.

Methods

The researchers employed a multi-pronged approach integrating bioinformatics and machine learning:

  • Data Acquisition and Preprocessing: Transcriptome data from IC/BPS patients and healthy controls were obtained from the Gene Expression Omnibus (GEO) database. Batch effects were corrected using the "sva" package in R.
  • Differential Gene Expression Analysis (DEGs): Standard statistical methods (limma package) were used to identify genes with significant expression differences between IC/BPS and control groups.
  • Functional Enrichment Analysis: Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Disease Ontology (DO) analyses were performed to understand the biological functions and pathways associated with the identified DEGs. Gene Set Enrichment Analysis (GSEA) was also used to explore pathway differences.
  • Weighted Gene Co-expression Network Analysis (WGCNA): This technique was used to identify modules of highly correlated genes and their association with IC/BPS, helping to uncover potential pathogenic genes.
  • Machine Learning for Biomarker Identification: Three distinct machine-learning algorithms—Random Forest (RF), LASSO (Least Absolute Shrinkage and Selection Operator), and SVM-RFE (Support Vector Machine-Recursive Feature Elimination)—were applied to pinpoint key genes that could serve as diagnostic markers. Genes identified by all three algorithms were considered crucial.
  • Diagnostic Model Construction and Validation: A nomogram model was built using the identified key genes. Its clinical utility was assessed using Decision Curve Analysis (DCA), calibration curves, and Receiver Operating Characteristic (ROC) curves to calculate the Area Under the Curve (AUC).
  • Immune Cell Landscape Analysis: The ssGSEA algorithm was used to quantify the infiltration levels of various immune cell types in IC/BPS and control samples.
  • In Vitro and In Vivo Validation: Key findings, particularly regarding PLAC8 expression and its functional impact, were validated using cell culture experiments (SV-HUC-1 cells) and immunohistochemistry (IHC) on clinical tissue samples.

Datasets

  • GEO Datasets: GSE11783, GSE28242, and GSE57560 were used for the initial bioinformatics analysis. These datasets comprised a total of 14 normal samples and 31 IC/BPS samples.
  • Clinical Samples: 8 bladder tissue samples from IC/BPS patients and 10 from unaffected controls (UC) were collected for validation through immunohistochemistry.

Key Insights and Ideas

  • Complex Immune Landscape in IC/BPS: The study reveals a significantly altered immune cell infiltration profile in IC/BPS patients compared to healthy individuals, highlighting the central role of immune dysregulation in the disease.
  • PLAC8 as a Multifaceted Biomarker: PLAC8 emerges not only as a potential diagnostic biomarker but also as a molecule that influences urothelial cell proliferation and modulates the PI3K/Akt/mTOR signaling pathway, suggesting a deeper involvement in the disease pathogenesis.
  • Integration of Bioinformatics and Machine Learning is Powerful: The combination of these approaches effectively narrowed down a large set of differentially expressed genes to a few key diagnostic candidates, demonstrating the power of such integrated strategies for complex diseases.
  • Potential for Non-Invasive Diagnostics: The identification of specific genes like PLAC8, S100A8, and PPBP as potential biomarkers opens the door for developing less invasive diagnostic methods for IC/BPS.

Key Results

  • 87 Differentially Expressed Genes (DEGs): 43 were upregulated, and 44 were downregulated in IC/BPS patients.
  • Three Key Diagnostic Genes Identified: PLAC8, S100A8, and PPBP were consistently identified by three different machine-learning algorithms.
  • High Predictive Power of Biomarkers: ROC curve analysis showed high AUC values for PLAC8 (0.887), S100A8 (0.818), and PPBP (0.871), indicating their potential as diagnostic biomarkers.
  • Upregulated PLAC8 in IC/BPS Tissues: Immunohistochemistry confirmed significantly higher PLAC8 expression in IC/BPS tissues compared to normal tissues.
  • PLAC8 Promotes Urothelial Cell Proliferation: In vitro experiments showed that PLAC8 overexpression enhanced SV-HUC-1 cell proliferation by inhibiting the PI3K/Akt/mTOR pathway, without affecting migration.
  • Increased Immune Cell Infiltration: The ssGSEA analysis revealed significantly higher infiltration of 23 types of immune cells in IC/BPS samples.

Limitations and Future Work

  • Limited Sample Size for Validation: The authors acknowledge that the model's validation was performed on a relatively small cohort of clinical samples, and further validation in larger, independent IC/BPS datasets is needed.
  • Need for Clinical Trials: While promising, the identified biomarkers and the role of PLAC8 require further clinical investigation and validation through prospective studies and clinical trials.
  • Elucidating Precise Mechanisms: While the study suggests PLAC8's role in the PI3K/Akt/mTOR pathway and immune cell modulation, further research is needed to fully understand the precise molecular mechanisms by which these factors contribute to IC/BPS pathogenesis.
  • Exploring Other Biomarkers: The study focused on transcriptomic data. Future work could explore other omics data (e.g., proteomic, metabolomic) to gain a more comprehensive understanding of IC/BPS.

Summary updated

Abstract

Our study identifies potential diagnostic candidate genes and reveals the complex immune landscape associated with IC/BPS. Among them, PLAC8 is a promising diagnostic biomarker that modulates the immune response in patients with IC/BPS, which provides new insights into the future diagnosis of IC/BPS.
BibTeX
@inproceedings{zhou2025identification,
  author = {Tao Zhou and Can Zhu and Wei Zhang and Qiongfang Wu and Mingqiang Deng and Zhiwei Jiang and Longfei Peng and Hao Geng and Zhouting Tuo and Ci Zou},
  title = {{Identification and validation of immune and diagnostic biomarkers for interstitial cystitis/painful bladder syndrome by integrating bioinformatics and machine-learning}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1511529},
}
Figure